Blocking IL-1 in Systemic Inflammation

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 2005 May 4

PMID 15867089

Citations 174

Authors

Charles A Dinarello

Affiliations

Soon will be listed here.

Abstract

A growing number of systemic inflammatory diseases characterized in part by recurrent fevers, leukocytosis, anemia, and elevated acute phase proteins are linked to interleukin (IL)-1 activity since rapid and sustained resolution is observed upon specific blockade of IL-1 receptors. Rapid resolution of systemic and local inflammation is now also reported in systemic onset juvenile idiopathic arthritis (SoJIA). Loss of control of the secretion of IL-1beta might be a common mechanism explaining the aberrant activity of IL-1 in these diseases.

Citing Articles

Cellular aspects of immunity involved in the development of atherosclerosis.

Khalaf K, Chamieh M, Welc N, Singh C, Kaouk J, Kaouk A Front Immunol. 2025; 16:1461535.

PMID: 39944697 PMC: 11813763. DOI: 10.3389/fimmu.2025.1461535.

Inflammation-Modulating Biomedical Interventions for Diabetic Wound Healing: An Overview of Preclinical and Clinical Studies.

Mahmoud N, Hamad S, Shraim S ACS Omega. 2024; 9(45):44860-44875.

PMID: 39554458 PMC: 11561615. DOI: 10.1021/acsomega.4c02251.

Identification and validation of ferroptosis related markers in erythrocyte differentiation of umbilical cord blood-derived CD34 cell by bioinformatic analysis.

Liu Q, Lin Z, Yue M, Wu J, Li L, Huang D Front Genet. 2024; 15:1365232.

PMID: 39139819 PMC: 11319168. DOI: 10.3389/fgene.2024.1365232.

Purinergic P2X7 receptor expression increases in leukocytes from intra-abdominal septic patients.

Martinez-Banaclocha H, Garcia-Palenciano C, Martinez-Alarcon L, Amores-Iniesta J, Martin-Sanchez F, Ercole G Front Immunol. 2023; 14:1297249.

PMID: 38094297 PMC: 10716420. DOI: 10.3389/fimmu.2023.1297249.

Anti-inflammatory and antioxidant activity of ursolic acid: a systematic review and meta-analysis.

Zhao M, Wu F, Tang Z, Yang X, Liu Y, Wang F Front Pharmacol. 2023; 14:1256946.

PMID: 37841938 PMC: 10568483. DOI: 10.3389/fphar.2023.1256946.

References

Smith D, Hanna R, Friend D, Moore H, Chen H, Farese A . The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity. 2003; 18(1):87-96. DOI: 10.1016/s1074-7613(02)00514-9. View

Economides A, Carpenter L, Rudge J, Wong V, Hartnett C, Pyles E . Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med. 2002; 9(1):47-52. DOI: 10.1038/nm811. View

Chae J, Komarow H, Cheng J, Wood G, Raben N, Liu P . Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell. 2003; 11(3):591-604. DOI: 10.1016/s1097-2765(03)00056-x. View

Gudipaty L, Munetz J, Verhoef P, Dubyak G . Essential role for Ca2+ in regulation of IL-1beta secretion by P2X7 nucleotide receptor in monocytes, macrophages, and HEK-293 cells. Am J Physiol Cell Physiol. 2003; 285(2):C286-99. DOI: 10.1152/ajpcell.00070.2003. View

Shoham N, Centola M, Mansfield E, Hull K, Wood G, Wise C . Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A. 2003; 100(23):13501-6. PMC: 263843. DOI: 10.1073/pnas.2135380100. View

Hawkins P, Lachmann H, Aganna E, McDermott M . Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum. 2004; 50(2):607-12. DOI: 10.1002/art.20033. View

Agostini L, Martinon F, Burns K, McDermott M, Hawkins P, Tschopp J . NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004; 20(3):319-25. DOI: 10.1016/s1074-7613(04)00046-9. View

Elssner A, Duncan M, Gavrilin M, Wewers M . A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol. 2004; 172(8):4987-94. DOI: 10.4049/jimmunol.172.8.4987. View

Kahlenberg J, Dubyak G . Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am J Physiol Cell Physiol. 2004; 286(5):C1100-8. DOI: 10.1152/ajpcell.00494.2003. View

10.

Andrei C, Margiocco P, Poggi A, Lotti L, Torrisi M, Rubartelli A . Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc Natl Acad Sci U S A. 2004; 101(26):9745-50. PMC: 470745. DOI: 10.1073/pnas.0308558101. View

11.

Dinarello C . Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res. 2004; 10(4):201-22. DOI: 10.1179/096805104225006129. View

12.

Verbsky J, White A . Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2004; 31(10):2071-5. View

13.

Colotta F, Dower S, Sims J, Mantovani A . The type II 'decoy' receptor: a novel regulatory pathway for interleukin 1. Immunol Today. 1994; 15(12):562-6. DOI: 10.1016/0167-5699(94)90217-8. View

14.

Dinarello C . Biologic basis for interleukin-1 in disease. Blood. 1996; 87(6):2095-147. View

15.

Mantovani A, Muzio M, Ghezzi P, Colotta C, Introna M . Regulation of inhibitory pathways of the interleukin-1 system. Ann N Y Acad Sci. 1998; 840:338-51. DOI: 10.1111/j.1749-6632.1998.tb09573.x. View

16.

Andrei C, Dazzi C, Lotti L, Torrisi M, Chimini G, Rubartelli A . The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol Biol Cell. 1999; 10(5):1463-75. PMC: 25302. DOI: 10.1091/mbc.10.5.1463. View

17.

Frenkel J, Wulffraat N, Kuis W . Anakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and Patel. Arthritis Rheum. 2004; 50(11):3738-9. DOI: 10.1002/art.20497. View

18.

Hoffman H, Rosengren S, Boyle D, Cho J, Nayar J, Mueller J . Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 2004; 364(9447):1779-85. PMC: 4321997. DOI: 10.1016/S0140-6736(04)17401-1. View

19.

Dierselhuis M, Frenkel J, Wulffraat N, Boelens J . Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford). 2005; 44(3):406-8. DOI: 10.1093/rheumatology/keh479. View

20.

Lovell D, Bowyer S, Solinger A . Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum. 2005; 52(4):1283-6. DOI: 10.1002/art.20953. View